Podcasts about biotech

When neuroscientist Madeline Lancaster was a brand new postdoc, she accidentally used an expired protein gel in a lab experiment and noticed something weird. The stem cells she was trying to grow in a dish were self-assembling. The result? Madeline was the first person ever to grow what she called a “cerebral organoid,” a tiny, 3D version of a human brain the size of a peppercorn.In about a decade, these mini human brain balls were everywhere. They were revealing bombshell secrets about how our brains develop in the womb, helping treat advanced cancer patients, being implanted into animals, even playing the video game Pong. But what are they? Are these brain balls capable of sensing, feeling, learning, being? Are they tiny, trapped humans? And if they were, how would we know?Special thanks to Lynn Levy, Jason Yamada-Hanff, David Fajgenbaum, Andrew Verstein, Anne Hamilton, Christopher Mason, Madeline Mason-Mariarty, the team at the Boston Museum of Science, and Howard Fine, Stefano Cirigliano, and the team at Weill-Cornell. EPISODE CREDITS: Reported by - Latif Nasserwith help from - Mona MadgavkarProduced by - Annie McEwen, Mona Madgavkar, and Pat Walterswith mixing help from - Jeremy BloomFact-checking by - Natalie Middleton and Rebecca Randand Edited by  - Alex Neason and Pat WaltersEPISODE CITATIONS:Videos - “Growing Mini Brains to Discover What Makes Us Human,” Madeline Lancaster's TEDxCERN Talk, Nov 2015 (https://zpr.io/6WP7xfA27auR)Brain cells playing Pong (https://zpr.io/pqgSqguJeAPK)Reuters report on CL1 computer launch in March 2025 (https://zpr.io/cdMf8Yjvayyd) Articles - Madeline Lancaster: The accidental organoid – mini-brains as models for human brain development (https://zpr.io/nnwFwUwnm2p6), MRC Laboratory of Molecular Biology What We Can Learn From Brain Organoids (https://zpr.io/frUfsg4pxKsb), by Carl Zimmer. NYT, November 6, 2025Ethical Issues Related to Brain Organoid Research (https://zpr.io/qyiATHEhdnSa), by Insoo Hyun et al, Brain Research, 2020 Brain organoids get cancer, too, opening a new frontier in personalized medicine (https://zpr.io/nqMCQ) STAT Profile of Howard Fine and his lab's glioblastoma research at Weill Cornell Medical Center: By re-creating neural pathway in dish, Stanford Medicine research may speed pain treatment (https://zpr.io/UnegZeQZfqn2) Stanford Medicine profile of Sergiu Pasca's research on pain in organoids A brief history of organoids (https://zpr.io/waSbUCSrL9va) by Corrò et al, American Journal of Physiology - Cell Physiology, Books - Carl Zimmer Life's Edge: The Search for What it Means to be Alive (https://carlzimmer.com/books/lifes-edge/)Sign up for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Signup (https://radiolab.org/newsletter)!Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today.Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org.Leadership support for Radiolab's science programming is provided by the Simons Foundation and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.

Welcome to this special episode of The Edge of Show, recorded live at the Future of Money, Governance & the Law Summit in Washington, D.C. In this episode, we dive deep into the transformative world of tokenization, exploring its impact on real estate, commodities, and beyond. Join our distinguished panel, moderated by Gerard Dache, featuring industry leaders like Benjamin Diggles, Jack Ding, Chris Smithmyer and Nadia Mihova.Key topics include:The difference between coins and tokensInfrastructure requirements for successful tokenizationReal estate tokenization and its potential to revolutionize transactionsThe importance of trust and governance in blockchain technologyInsights into the Blockchain Maturity Model and its role in selecting the right blockchainTogether, they discuss the essential technology infrastructure for tokenization, real-world use cases, and the future of blockchain in various industries.Don't forget to subscribe, rate, and share this episode with friends who are eager to learn more about the cutting edge of Web3!Support us through our Sponsors! ☕

Trevor Maxwell lived the archetype of masculinity in rural Maine. Big, strong, splitting wood, raising kids, and carrying the load. Then cancer ripped that script apart. In 2018 he was bedridden, emasculated, ashamed, and convinced his family would be better off without him. His wife refused to let him disappear. That moment forced Trevor to face his depression, get help, and rebuild himself. Out of that came Man Up To Cancer, now the largest community for men with cancer, a place where men stop pretending they are bulletproof and start being honest with each other.Eric Charsky joins the conversation. A veteran with five cancers, forty-nine surgeries, and the scars to prove it, Eric lays out what happens when the military's invincible mindset collides with mortality. Together, we talk masculinity, vulnerability, sex, shame, and survival. This episode is blunt, raw, and overdue.RELATED LINKSMan Up To CancerTrevor Maxwell on LinkedInDempsey CenterEric Charsky on LinkedInStupid Cancer FEEDBACKLike this episode? Rate and review Walk It Off on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The New Year begins with biotech running along parallel storylines. There's cause for optimism as the industry's financing gears have begun to churn again and innovation remains as strong as it has ever been, while there's cause for concern as the world's most stable, progressive, science-based regulatory system has become unpredictable amid new leadership at HHS, FDA, and NIH. On the first episode of the BioCentury This Week podcast's seventh year, BioCentury's analysts assess the state of play for biotech in the U.S., Europe, and Asia.The discussion ranges from recent changes at NIH to what's next for rare pediatric disease priority review vouchers, and from Europe's opportunity as FDA enters uncertain terrain to Japan's evolving biotech landscape.Early bird rates for BioCentury and BayHelix's fifth East-West Biopharma Summit end Friday. Act now to join investors, dealmakers and innovators in Seoul this March to source innovation from Asia, or accelerate your own pipeline by finding the right Asia partner.View full story: https://www.biocentury.com/article/657978#BiotechOutlook #FDAUncertainty #GlobalBiotech #RarePediatricDiseasePRV #NIHLeadership00:00 - Introduction01:46 - 2026 Outlook03:56 - Policy Landscape11:48 - Priority Review Vouchers15:03 - Global Perspectives16:57 - Spotlight on Japan21:55 - European Biotech OpportunitiesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In der ersten Folge des neuen Jahres liefern die Finanzjournalisten Dietmar Deffner und Holger Zschäpitz wieder ihre 26 Investment-Ideen für das Börsenjahr 2026. Der Anspruch ist hoch: In den vergangenen drei Jahren erzielten die Ideen im Schnitt deutlich zweistellige Renditen. Jetzt geht es darum, diese Erfolgsserie fortzuschreiben. DEFFNER & ZSCHÄPITZ sind wie das wahre Leben. Wie Optimist und Pessimist. Im wöchentlichen WELT-Podcast diskutieren und streiten die Journalisten Dietmar Deffner und Holger Zschäpitz über die wichtigen Wirtschaftsthemen des Alltags. Schreiben Sie uns an: wirtschaftspodcast@welt.de Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutzerklärung: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

As we all learned in 2020, getting ahead of the next major pandemic is a matter of global concern. For the Coalition for Epidemic Preparedness Innovations, or CEPI (cepi.net), it is their reason for existing. Joining me for this conversation are Valentina Bernasconi, Head of Laboratory Science for CEPI, and Marie-Eve Poupart, Lead Scientist In Charles River's Immunology department. Together we discuss CEPI's progress so far, how Charles River is contributing to the cause, and how we can plan for the unknown Disease X while simultaneously handling current outbreaks of deadly diseases like Ebola, Marburg, Nipah virus, Lassa Fever, and chikungunya.

We love to hear from our listeners. Send us a message. This week's special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and reporting that mattered most in 2025, and what each editor has planned for 2026. From the RNA, cell, and gene therapy space to small molecule manufacturing, bioprocessing, drug discovery, and outsourcing, the editors weigh in on key industry trends, new developments, and policy surprises from their respective coverage areas. Topics include biotech funding dynamics, FDA leadership, China's growing role, favorite holiday movies, and much, much more. Special thanks to Tyler Menichiello and the Better Biopharma podcast for hosting this roundtable discussion. Happy New Year!     Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Michele Schneider with MarketGuage explains the themes she's watching in what she calls a "fire horse" market this year. She likes robotics, biotech and crypto heading into 2026 and has an eye on small caps. However, Michele urges investors watch for persistent inflation and price impact on everyday goods as a test against American consumers. ======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

In this episode of Culture Architects, David Friedman interviews Brian Cali, a molecular biologist turned entrepreneur and investor. Brian shares his journey from a young science enthusiast to co-founding Ironwood Pharmaceuticals, emphasizing the importance of relationships, culture, and collaboration in building successful companies. As Ironwood grew, Brian navigated the challenges of maintaining a healthy company culture and adapting to organizational complexity. After a successful career in biotech, he transitioned to climate advocacy, focusing on community building and empowering others to engage in climate action. Brian's story highlights the significance of intentionality in leadership and the ripple effect of decisions made within organizations.

January brings fresh biotech hiring budgets, energized hiring managers, and real momentum after a tough 2025. If you've been waiting for the right time to level up your biotech career, this is it.In this episode, you'll discover:Why January is the best month to apply for biotech jobs after a slow DecemberHow the December Networking Challenge helped members grow their LinkedIn reach and profile visibilityThe Application Challenge launches January 6th with five days of live teaching to build daily job search habitsAn annual career planning session on January 12th to map your 2026 goalsA presentation skills workshop that can accelerate both job offers and promotionsA 10-week AI course to help you work smarter and meet employer expectations in 2026The Fire Horse approach to bringing bold, unstoppable energy to your career goalsWhether you're job searching, seeking a promotion, or building new professional skills, this episode gives you the roadmap and momentum to make 2026 your breakthrough year.Join our Biotech Career Coach Skool community and start the year with structure, support, and a community that gets it.Learn more about the Collaboratory Career Hub community and access our free resources:Join our Skool CommunityTake the Free 7-day Interview Sprint ChallengeCheck out our sister podcast: Building BiotechsSend Carina a connection request on LinkedIn!Stay connected with us:

Welcome to this special episode of The Edge of Show, recorded live at the Future of Money, Governance & the Law Summit in Washington, D.C. This conversation brings together leaders from Web3, finance, policy, and infrastructure to tackle a critical question: how do we fund innovation while building long-term trust, inclusion, and resilience?Moderated by Nadya Rousseau, this panel features Vincent Kadar, Kevin Jackson, Andrew Durgee, and Terry Culver, offering rare insight into how capital formation is evolving through tokenization, public-private collaboration, decentralized infrastructure, and access to private markets.The discussion explores real-world asset tokenization, the role of regulation, the limits of first-mover advantage, and why collaboration, not isolation, is becoming the defining strategy for sustainable innovation. From retail access to pre-IPO assets to DAOs, grants, and hybrid funding models, this episode breaks down how Web3 is reshaping who gets to participate in the global economy.If you're building, investing, shaping policy, or trying to understand where finance and innovation are heading next, this episode delivers clear perspectives from leaders actively building the future not theorizing about it.Support us through our Sponsors! ☕

As 2025 wraps, we break down the year's top market drivers. Biotech deals dominated the sector, will the M&A momentum continue in 2026? Plus, it's the end of an era for Berkshire Hathaway as Warren Buffett steps down. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Data in Biotech, Ross Katz chats with Mitra Mosharraf, Chief Scientific Officer at HTD Biosystems, about how AI and machine learning are revolutionizing nanomedicine. They explore the use of AI in drug discovery, formulation, manufacturing, and clinical development, highlighting how data-driven strategies are improving safety, reducing costs, and enabling more personalized therapies in the biotech space. What you'll learn in this episode: >> How AI and ML reduce costs and increase success rates in nanomedicine development. >> Key challenges in nano drug delivery and how machine learning helps overcome them. >> How HTD Biosystems' iFormulate platform speeds up formulation with predictive modeling. >> How wearables and real-time data are reshaping clinical trial design. >> The future of personalized and automated drug delivery systems. Meet our guest Mitra Mosharraf is the Chief Scientific Officer at HTD Biosystems and co-founder of Engimata Inc. With 20+ years of experience, she leads innovation in biologics, nanomedicine, and lipid-based delivery systems. Mitra is a recognized thought leader in pharmaceutical sciences. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Mitra Mosharraf on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Nathan Moser, Sr. expects GDP to surprise to the upside next year and makes the bull case for U.S. small caps. He especially sees opportunities in biotech and shares several picks, including Pacira Biosciences (PCRX) and SI-Bone (SIBN). “Many of the great medtech companies are eventually acquired,” he notes as well.======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating stories that underscore the dynamic nature of our industry, where scientific innovation meets real-world application.Starting with a significant advancement in gene therapy, researchers have made remarkable progress in a novel approach to treating rare genetic disorders. This new methodology involves the use of CRISPR technology to edit genes directly within the human body, paving the way for potential cures once thought impossible. By targeting specific DNA sequences, scientists can now correct genetic mutations at their source. This breakthrough not only promises to transform the treatment landscape for rare diseases but also enhances our understanding of genetic disorders at a molecular level. The implications here extend beyond rare conditions, potentially offering new avenues for tackling more common genetic diseases in the future.Moving forward, let's discuss recent regulatory developments that have caught the industry's attention. The FDA has granted accelerated approval to a new oncology drug that shows promise in treating advanced forms of breast cancer. This decision was based on compelling clinical trial results demonstrating significant improvements in patient survival rates compared to existing therapies. The drug targets specific proteins involved in tumor growth, offering a more precise treatment option with potentially fewer side effects. This approval exemplifies how regulatory bodies are adapting to expedite access to life-saving treatments while ensuring rigorous safety and efficacy standards.In another noteworthy development, a Phase III clinical trial has yielded positive results for a novel Alzheimer's drug. The trial demonstrated that this drug significantly slows cognitive decline in patients with early-stage Alzheimer's disease. By targeting amyloid plaques in the brain, which are believed to contribute to neurodegeneration, this therapeutic approach represents a potential shift in how we treat this debilitating condition. These findings provide hope for millions affected by Alzheimer's and underscore the importance of continued investment in neuroscience research.Turning our attention to infectious diseases, there's exciting news from a biotech company focusing on vaccine development. They've announced encouraging preliminary data from trials of their new mRNA-based vaccine for respiratory syncytial virus (RSV). RSV is known for causing severe respiratory illness, particularly in infants and the elderly. The vaccine demonstrated robust immune responses and a favorable safety profile, suggesting it could become an important tool in preventing RSV infections globally. This development highlights the versatility of mRNA technology, which has already revolutionized COVID-19 vaccine design and holds promise for addressing various infectious diseases.In terms of industry trends, one cannot overlook the growing emphasis on personalized medicine. Recent advancements in biomarker research are enabling more tailored therapeutic approaches across multiple disease areas. By identifying specific genetic or molecular markers associated with diseases, healthcare providers can better predict patient responses to certain treatments. This shift towards precision medicine not only improves patient outcomes but also enhances healthcare efficiency by reducing trial-and-error prescribing.Lastly, we delve into an intriguing area of metabolic disorders where innovative therapeutic strategies are emerging. A biotech firm has developed a first-in-class oral medication for treating non-alcoholic steatohepatitis (NASH), a serious liver condition linked to obesity and metabolic syndrome. The drug works by modulating key metabolic pathways involved in liver inflammation and fibrSupport the show

The most anticipated annual tradition on Out of Patients returns with the 2025 Holiday Podcast Spectacular starring Matthew's twins Koby and Hannah. Now 15 and a half and deep into sophomore year, the twins deliver another unfiltered year end recap that longtime listeners wait for every December. What began as a novelty in 2018 has become a time capsule of adolescence, parenting, and how fast childhood burns off.This year's recap covers real moments from 2025 A subway ride home with a bloodied face after running full speed into that tree that grows in Brooklyn. Broadway obsessions fueled by James Madison High School's Roundabout Youth Ensemble access, including Chess, & Juliet, Good Night and Good Luck, and Pirates of Penzance holding court on Broadway. A Disneylanmd trip where the Millennium Falcon triggered a full system reboot. A New York Auto Show pilgrimage capped by a Bugatti sighting. All the things.The twins talk school pressure, AP classes, learner permit anxiety, pop culture fixation, musical theater devotion, and the strange clarity that comes with turning 15. The humor stays sharp, the details stay specific, and the passage of time stays undefeated. This episode lands where the show works best: family, honesty, and letting young people speak for themselves.FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This past year was an inflection point for biotech: The markets woke up, M&A and China had strong showings, drug development offered key trends, and new leadership at FDA shuffled the regulatory deck. On the latest BioCentury This Week podcast, BioCentury's analysts make their picks for the biggest biopharma readouts, deals and regulatory and policy moves of 2025 and what they are forecasting for the year ahead.The analysts also recap biotech highlights of the past two weeks, including the $4.8 billion takeout of Amicus Therapeutics by BioMarin Pharmaceutical.View full story: https://www.biocentury.com/article/657933#BiotechOutlook2026 #BiopharmaTrends #BiotechMA #FDALeadership #ChinaBiotech00:00 - Introduction 02:31 - BioMarin's $4.8B Amicus Deal06:07 - Year-end Biotech Highlights16:37 - Analyst Picks and Predictions30:01 - Policy and Regulatory LandscapeTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Breakthrough science has never been stronger — yet patients still miss life-saving therapies.Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery.The problem isn't discovery. It's how science, capital, and systems are aligned — or not.Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem.As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge scientific depth with incentives, execution, and real-world delivery. Capital follows speed and scale — not intention — and healthcare systems built decades ago are failing to keep up.In this episode, Alasdair Milton, Principal at KPMG, explains where innovation actually breaks — and what must change for cures to reach patients at scale. From diagnostics and data silos to capital allocation and prevention models, this conversation reframes the next decade of precision medicine.

Inato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRO and Site Network: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy CRC Academy: http://www.TheCRCacademy.comLatinos In Clinical Research: http://www.LatinosinClinicalResearch.comThe University Of Clinical Research: https://www.theuniversityofclinicalresearch.com/My TikTok: DanSfera

When a high-achieving scientist realized the traditional definition of success no longer fit, she chose a radically different path. In this episode, Brie shares how she walked away from a predictable biotech career, trusted her instincts, and built a portfolio-style consulting business that aligns with her values, energy, and love for animal welfare.   What you'll learn How to recognize when your "successful" career no longer feels meaningful Why trusting your instincts is essential when your values begin to shift How career experiments (like Social Goldilocks) can reveal unexpected paths What it takes to design a more flexible, values-aligned version of success   Our book, Happen To Your Career: An Unconventional Approach To Career Change and Meaningful Work, is now available on audiobook! Visit  happentoyourcareer.com/audible to order it now! Visit happentoyourcareer.com/book for more information or buy the print or ebook here! Want to chat with our team about your unique situation? Schedule a conversation   Free Resources What career fits you? Join our free 8 Day Mini Course to figure it out! Career Change Guide - Learn how high-performers discover their ideal career and find meaningful, well-paid work without starting over.   Related Episodes Designing Career Experiments and Testing New Careers (Spotify / Apple Podcasts) Discover Your Strengths to Find Your Ideal Career (Spotify / Apple Podcasts) Social Goldilocks Experiment (Watch Here)

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Nick Manusos, CEO at Kenai Therapeutics, talks about his experiences building cell therapy spinouts from FujiFilm Cellular Dynamics, learning from big pharma decision-making processes, and dosing the first patient with Kenai's allogeneic neuron replacement cell therapy for Parkinson's disease. Nick also talks about funding an early-stage cell therapy company and forging key manufacturing and therapy administration partnerships. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Dr. Christina Rahm has worked as a medical, clinical, and research scientist in the pharmaceutical, nutraceutical, and biotechnology industries for Janssen, Johnson & Johnson, Biogen Idec/Biogen, UCB, Bristol Meyers Squibb, and Alexion. Additionally, she worked on the corporate side for Pfizer, Biogen, and Janssen and is currently the Chairman of International Science Nutrition Society and Chief Science Officer for ROOT Wellness. Dr. Rahm has also served as a formulator for several companies and manufacturing labs, including her own. She has created multiple provisional patents, proprietary formulas, and trade secrets in addition to authoring her first book, Cure the Causes: Live the Life you Want, Not the One Prescribed. Through years of laboratory research and ethical observations, she has developed a personalized and predictive consulting company working on everything from the environment to DNA and detox wellness plans in which Dr. Rahm helps clients reset their bodies and minds to be spiritually, mentally, emotionally, and physically balanced.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some fascinating breakthroughs and regulatory updates that are shaping the future of healthcare.Starting with a pivotal advancement in Alzheimer's research, a new drug has shown promising results in slowing cognitive decline in patients with early-stage Alzheimer's disease. This innovative therapy targets amyloid plaques in the brain, which are believed to play a central role in the progression of Alzheimer's. Recent clinical trials have demonstrated that patients receiving this treatment experienced a significant reduction in the rate of cognitive deterioration compared to those on a placebo. The implications of this development are profound, offering hope for millions affected by this debilitating condition. As researchers continue to unravel the mysteries of Alzheimer's, this breakthrough marks a crucial step forward in understanding and potentially halting disease progression.Moving on to regulatory news, the FDA has recently granted accelerated approval to a novel gene therapy for a rare genetic disorder known as spinal muscular atrophy (SMA). This condition, which affects motor neurons and leads to muscle wasting and weakness, primarily impacts infants and young children. The newly approved therapy works by delivering a functional copy of the defective gene directly into the patient's cells. Early trials have shown remarkable improvements in motor function and survival rates among treated infants. This approval represents not only a lifeline for affected families but also underscores the growing potential of gene therapies to address previously untreatable genetic diseases.In another significant development, researchers have unveiled a groundbreaking study on an experimental cancer vaccine that has demonstrated efficacy in preventing tumor growth in preclinical models. Unlike traditional vaccines aimed at infectious diseases, this cancer vaccine is designed to harness the body's immune system to specifically target and destroy cancer cells. The study's results indicate that the vaccine was successful in generating a robust immune response, which significantly inhibited tumor progression. If these findings can be replicated in human trials, it could open new avenues for cancer prevention and treatment, particularly for cancers with limited therapeutic options.Shifting our focus to trends within the industry, there's an increasing emphasis on personalized medicine, reflecting a broader shift towards treatments tailored to individual patients' genetic profiles. This approach aims to optimize therapeutic efficacy while minimizing adverse effects by considering each patient's unique genetic makeup. Advances in genomic sequencing technologies and bioinformatics are driving this transformation, enabling more precise diagnostics and targeted therapies. As personalized medicine continues to evolve, it holds the promise of revolutionizing how diseases are treated and managed in clinical practice.On the topic of drug approvals, a new oral medication for type 2 diabetes has received regulatory clearance after demonstrating superior glycemic control compared to existing treatments. This drug belongs to a novel class of medications that enhance insulin sensitivity and reduce glucose production by targeting specific metabolic pathways. Clinical trials indicated significant improvements in blood sugar levels and overall metabolic health among participants. Given the global prevalence of type 2 diabetes and its associated health complications, such advancements are crucial for improving patient outcomes and reducing healthcare burdens.Lastly, focusing on collaborations within the industry, several prominent pharmaceutical companies have announced partnerships aimed at accelerating research in infectious diseases.Support the show

I Sold My Biotech, Exposed Cheating Wife & Lover, Then Seized Everything for My Ultimate RevengeBecome a supporter of this podcast: https://www.spreaker.com/podcast/true-cheating-wives-and-girlfriends-stories-2025-true-cheating-stories-podcast--5689182/support.

I Sold My Biotech, Exposed Cheating Wife & Lover, Then Seized Everything for My Ultimate RevengeBecome a supporter of this podcast: https://www.spreaker.com/podcast/true-cheating-wives-and-girlfriends-stories-2025-true-cheating-stories-podcast--5689182/support.

In this episode of Data in Biotech, Ross Katz chats with Jaidev Chakka, Principal Scientist at the University of Mississippi School of Pharmacy, about how 3D bioprinting and AI are reshaping pharmaceutical manufacturing. They explore the development of custom scaffolds for tissue engineering, the integration of gene delivery systems, and how data-driven approaches are enabling smarter, more scalable solutions in personalized medicine. What you'll learn in this episode: >> How 3D printing is enabling customized bone scaffolds and regenerative therapies >> The role of AI in optimizing pharmaceutical 3D printing parameters >> How organoids can act as micro-organs for testing and computation >> The promise and challenge of personalized, on-demand drug manufacturing >> Why collaboration between data scientists and biopharma researchers is critical Meet our guest LR Jaidev Chakka is a Principal Scientist at the University of Mississippi School of Pharmacy, pioneering 3D bioprinting, drug delivery, and organoid research to revolutionize patient care and pharma manufacturing. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Jaidev Chakka on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Welcome to this special Christmas Eve episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) hosted by Edge of Company with the Government Blockchain Association, this special captures live insights from industry leaders like Yat Siu, Brittany Keisser and Bill Foster on tokenization, blockchain policy, and decentralized ecosystems near the White House. Key TakeawaysYat Siu talks about how tokenization emerges as a transformative force, enabling network ownership, stablecoin expansion to unbanked populations, and AI agency through fixed blockchain rules. Bill Foster addresses permissioned blockchains, identity verification via mobile IDs, and stablecoin risks like bailouts. Brittany Kaiser champions data ownership, Telegram's TON blockchain for ethical social media, and privacy-preserving AI networksDiscussions explore how blockchain, AI, stablecoins, and data rights are reshaping finance, regulation, and global innovation.​We wish you a very Happy Holidays!! Support us through our Sponsors! ☕

Jason Gilley walked into adulthood with a fastball, a college roster spot, and a head of curls that deserved its own agent. Cancer crashed that party and took him on a tour of chemo chairs, pediatric wards, metal taste, numb legs, PTSD, and the kind of late night panic that rewires a kid before he even knows who he is.I sat with him in the studio and heard a story I know in my bones. He grew up fast. He learned how to stare down mortality at nineteen. He found anchors in baseball, therapy, and the strange friendships cancer hands you when it tears your plans apart. He owns the fear and the humor without slogans or shortcuts. Listeners will meet a young man who refuses to let cancer shrink his world. He fights for the life he wants. He names the truth without apology. He reminds us that survivorship stays messy and sacred at the same time. This conversation will stay with you.RELATED LINKS• Jason Gilley on IG• Athletek Baseball Podcast• EMDR information• Children's Healthcare of AtlantaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A Year of Biotech Bytes: Reflections, Stories, and Honest Moments#biotechbytes #biotechpodcast #behindthemicThis episode is a look back at the year, the lessons we learned, and the moments that shaped Biotech Bytes. Please visit our website to get more information: https://swangroup.net/I'm joined by Mary Louise Smith, the voice, support, and good energy behind every episode. She's the person many listeners never see, yet she's a major part of why this podcast runs the way it does. We talk about how Biotech Bytes really started, why simple conversations often lead to the best ideas, and how AI can help us focus on the work that matters most. Mary also shares what leadership looks like behind the scenes and a few personal stories that shaped our year, including our shared love for chocolate.If you've listened this year, thank you for being part of this community. Let us know what topics or guests you want to hear in the new year.Links from this episode:Get to know more about Bill Wallace: https://www.linkedin.com/in/williamwallace2Learn more about Intercept Pharmaceuticals:https://www.interceptpharma.com

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jennifer Sheller, SVP and Head of Global Clinical Trial Operations at Merck talks about simplifying trial protocols and what she likes about Merck's hybrid functional service provider model for conducting trials in over 60 countries. Jennifer shares her experiences integrating Merck's acquisitions without breaking studies or losing people, using new technology to improve trial operations, and co-designing studies with trial sites for agility and speed.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode of Data in Biotech, Ross Katz sits down with Callie Celichowski and Isa Kupke from Veloxity Labs to discuss how their CRO leverages speed, precision, and innovation to support drug development. Learn how they use mass spectrometry, cloud-based infrastructure, and hands-on client partnerships to drive rapid, high-quality bioanalytical insights that support everything from preclinical studies to FDA submissions. What you'll learn in this episode: >> Why "speed with purpose" is essential for bioanalytical CROs supporting biotech and pharma clients >> The benefits and challenges of working with peptides and GLP-1 receptor agonists >> How the SCIEX 8600 enhances detection of low-concentration analytes Meet our guests Isa Kupke is Scientist II at Veloxity Labs, where she specializes in mass spectrometry and method development for preclinical and regulated bioanalytical programs. She also co-founded Blyde Botanics, bridging plant-based science and product development. Callie Celichowski is Senior Director of Business Development at Veloxity Labs, with over two decades in the pharmaceutical and CRO space. She's recognized for building strategic client partnerships and driving rapid, data-driven decision-making. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Isa Kupke on LinkedIn Connect with Callie Celichowski on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the ever-evolving landscape of pharmaceuticals and biotechnology, a series of strategic transactions and scientific advancements are reshaping the industry.BioMarin's acquisition of Amicus Therapeutics for $4.8 billion is a significant highlight, marking the company's largest transaction to date. This move signifies a strategic pivot towards enhancing its capabilities in the rare disease sector, leveraging Amicus's expertise and robust pipeline to potentially improve patient outcomes in this highly specialized area. This acquisition is expected to enrich BioMarin's portfolio significantly with promising assets from Amicus, reflecting a strategic shift under new leadership towards rare disease treatments.Regulatory affairs have seen considerable activity as well, with the FDA raising concerns over manufacturing practices at Catalent's gene therapy facility. These issues, documented in a Form 483 following inspections, particularly pertain to the production of Elevidys. Such regulatory scrutiny emphasizes the critical importance of maintaining compliance with manufacturing standards in gene therapy—a burgeoning field within biotech that holds immense promise for treating genetically-driven conditions.The FDA's oversight extends beyond manufacturing practices to advertising, as evidenced by an untitled letter issued to Bristol Myers Squibb regarding their Cobenfy TV ad. This action is part of the FDA's broader initiative to ensure that direct-to-consumer marketing materials accurately portray drug benefits and risks, thereby protecting public health.In another strategic move, Alvotech and Teva are gearing up for the 2026 U.S. launch of an Eylea biosimilar following a settlement with Regeneron. This development highlights the competitive dynamics within the biosimilar market—a segment poised for growth as patents on major biologics expire, offering more cost-effective alternatives and expanding treatment access.Meanwhile, Clovis Oncology has achieved a milestone with Rubraca, which transitioned from accelerated approval to full FDA endorsement for prostate cancer treatment after five years. This progression underscores Rubraca's demonstrated efficacy and safety profile in addressing advanced prostate cancer—a notable achievement amid an increasingly competitive oncology market.Policy changes proposed by Health and Human Services Secretary Robert F. Kennedy Jr. could have profound implications by disrupting funding streams for hospitals providing gender-affirming care to minors. The potential impact on healthcare providers and patients who rely on these services is significant.Turning to clinical trials, Daiichi Sankyo has seen success with Enhertu receiving FDA approval for first-line HER2-positive breast cancer treatment. Nonetheless, challenges persist as a separate phase 3 trial for another antibody-drug conjugate was paused due to unexpected patient deaths. Meanwhile, Takeda plans to seek FDA approval for its TYK2 inhibitor following successful phase 3 trials in psoriasis—indicating promising potential in autoimmune disease therapies.Strategic shifts are evident across organizations as well, highlighted by Kathy Fernando's departure from Pfizer to join Replicate Bioscience as Chief Business Officer. Her new role focuses on advancing Replicate's self-replicating RNA technology platform—an area gaining traction due to its implications for vaccine development and therapeutic applications.On the clinical trials front, Altimmune reported encouraging results from a 48-week study on metabolic dysfunction-associated steatohepatitis (MASH). Their GLP-1/glucagon dual receptor agonist demonstrated sustained weight loss and improvements in non-invasive liver fibrosis measures—offering new hope for MASH patients who face limited treSupport the show

Returning guest Dean McAlister, EVP, Inizio Biotech, has spent over 35 years in Fortune 500 pharma leadership, including nearly 3 decades at AstraZeneca. Hear how to prepare to lead in an uncertain environment, how to develop conscious competence as a leadership skill, how to become more adaptable as a leader, how to stop your ego from getting in the way as a leader, and how to build the courage to say what needs to be said in meetings. Connect with Shirley at ShirleyKavanagh.com and on LinkedIn, and Dean on LinkedIn

A Note from James:One of my favorite conversations on this show was with Peter Thiel. Yes—PayPal, Facebook, Palantir, and a dozen other hits. I first ran this episode years ago, and the advice still holds up. The same stories, the same frameworks—and the same challenge to think from first principles. Here's Peter Thiel, one of the most influential entrepreneurs of our time. Episode Description:In this redux, James pressure-tests the core ideas from Peter Thiel's Zero to One—why competition is for losers, how real monopolies are built, and why starting “narrow” is often the only path to something huge. They cover Facebook's early moat (real identity), PayPal's network-effect wedge on eBay, and the “10x or nothing” bar for proprietary technology. Peter shares a contrarian read on bubbles, why biotech's slump may be opportunity, and how to hire, divide roles, and keep teams from fighting. The through-line: seek secrets, combine disciplines, and make something so different that it becomes its own category. What You'll Learn:How to pick markets the Zero to One way: start with a “small, winnable monopoly,” then expand in concentric circles. The four classic moats—and which to favor first: proprietary tech, network effects, economies of scale, and brand (with a bias toward real tech). A practical rule for virality vs. network effects: growth is a tactic; enduring value comes from the network that forms once users arrive. Team design that prevents internal warfare: make roles uniquely owned; if two people own the same thing, you're paying for a fight. How to hunt “secrets”: believe they exist, look where consensus is stale, and borrow from adjacent fields to see what specialists miss. Timestamped Chapters:[02:00] A Note from James — Why this conversation still ranks among the best. [03:00] Zero to One, in one line — “Do something new, different, fresh, strange.” [05:17] Competition vs. Capitalism — Why perfect competition kills profits; aim for uniqueness. [07:28] Facebook's original edge — Real identity as the breakthrough vs. MySpace's alt-persona culture. [09:14] Bits vs. Atoms — Stagnation outside software and how biology could become an information science. [12:05] Personality and perseverance — Why mild contrarian wiring helps founders ignore status games. [15:21] “10x or nothing” — The technology and/or experience must be an order of magnitude better. [17:00] Monopoly thinking, ethically done — Create abundance by creating something truly new. [23:30] The PayPal pre-history — Why long-running trust among teammates births more companies. [30:10] Early Facebook investment logic — College-only looked “small,” which was exactly the point. [32:03] Turning down $1B — The boardroom debate, optionality, and founder conviction. [36:23] Moats in practice — Picking the right advantage (and why brand alone is shaky). [37:06] Network effects ≠ virality — How value compounds after growth. [39:54] PayPal's wedge — eBay power-sellers and the $10 incentive as a growth accelerant. [41:22] Beware the “Chinese refrigerator” TAM slide — Start small, win big. [42:01] Uber vs. Airbnb — Investor bias and why some models get over- or undervalued. [44:18] Bubbles and the public — What changes across tech, housing, and today's “government bubble.” [48:00] War on cash & credit — Why Peter favors unlevered, opaque innovation over fixed income. [51:10] Biotech headwinds (and upside) — Regulation, Eroom's Law, and why sentiment can misprice breakthroughs. [53:50] Secrets — If you assume they exist, you'll be the one to find them. [57:56] Interdisciplinary bets — CS × biology; CS × transportation; why university silos miss the action. [59:51] Silicon Valley on HBO — The “Peter Gregory” caricature and what the show gets right. Additional Resources:Zero to One: Notes on Startups, or How to Build the Future (book) — Amazon hardcover. AmazonFounders Fund — Peter Thiel profile (bio & portfolio highlights). Founders Fund“PayPal Mafia” overview (alumni companies: YouTube, Yelp, LinkedIn, Tesla, SpaceX, Palantir, Yammer). WikipediaYahoo's 2006 $1B offer for Facebook (background reporting). Business InsiderEroom's Law (pharma R&D productivity; Nature Reviews Drug Discovery). NatureSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Scott Wren of Wells Fargo Investment Institute on global strategy and positioning, plus Steve Liesman wraps his key interview with Fed Governor Christopher Waller. Apple's outlook with Craig Moffett of MoffettNathanson. The Goldman biotech outlook with Salveen Richter of Goldman Sachs. Next week's market catalysts with Adam Crisafulli of Vital Knowledge. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join us for an insightful episode of The Edge of Show as we dive into the world of decentralized AI finance with Ron Bodkin, co-founder and CEO of Theoriq Labs. With over 15 years of experience in applied AI, Ron shares his journey from working at tech giants like Google to pioneering a decentralized AI protocol that empowers autonomous agents to manage capital and execute strategies on-chain.In this episode, we explore:The intersection of AI and blockchain technologyThe importance of decentralization in the future of financeHow Theoriq Labs is leveraging AI agents to enhance DeFi strategiesThe challenges and opportunities in creating a decentralized ecosystemInsights into the future of capital markets and the role of AI agentsWhether you're a crypto enthusiast, a tech innovator, or just curious about the future of finance, this episode is packed with valuable insights and thought-provoking discussions.Don't forget to like, subscribe, and hit the notification bell to stay updated on our latest episodes!Support us through our Sponsors! ☕

Dr. Marissa Russo trained to become a cancer biologist. She spent four years studying one of the deadliest brain tumors in adults and built her entire research career around a simple, urgent goal: open her own lab and improve the odds for patients with almost no shot at survival. In 2024 she applied for an F31 diversity grant through the NIH. The reviewers liked her work. Her resubmission was strong. Then the grant system started glitching. Dates vanished. Study sections disappeared. Emails went silent. When she finally reached a program officer, the message was clear: scrub the DEI language, withdraw, and resubmit. She rewrote the application in ten days. It failed. She had to start over. Again. This time with her identity erased.Marissa left the lab. She found new purpose as a science communicator, working at STAT News through the AAAS Mass Media Fellowship. Her story captures what happens when talent collides with institutional sabotage. Not every scientist gets to choose a Plan B. She made hers count.RELATED LINKSMarissa Russo at STAT NewsNIH F31 grant story in STATAAAS Mass Media FellowshipContact Marissa RussoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to this episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) event in Washington, D.C. In this conversation, Josh Kriger is joined by Josh Lawler, Cathy Hackl, Nicholas Zaldastani, and Janet Adams as they unpack the global race toward artificial general intelligence (AGI) and why decentralization may be the key to building ethical, transparent, and inclusive AI systems.The discussion dives into agentic AI, decentralized infrastructure, trust networks, data ownership, deepfakes, humanoid robotics, and the growing risks of centralized control. From real-world AI governance challenges to the role blockchain can play in accountability and verification, this episode cuts through the hype and focuses on what actually needs to be built and fixed.If you're building, investing, or simply trying to understand where AI and Web3 are heading next, this conversation offers clear insights from leaders working at the edge of innovation.Watch now and join the conversation shaping the future of intelligence.Support us through our Sponsors! ☕

Welcome to this episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) event in Washington, D.C. In this conversation,Josh Kriger is joined by Craig Salm, Ryan VanGrack, Kyle Hauptman, and Jon Ungerland for a candid breakdown of the rapidly evolving world of FinTech, blockchain, and digital assets. Together, they dig into regulatory clarity, the rise of DeFi, shifting consumer behaviors, and what recent policy moves mean for the future of money.Key Highlights:How regulatory uncertainty impacts builders, investors, and institutionsThe rise of DeFi and new expectations around decentralized servicesWhat recent SEC changes signal for digital assetsHow local financial institutions adapt to new money networksPredictions for the future of money and innovation in U.S. financeThis episode is for policymakers, innovators, and industry leaders who want to explore how emerging technologies are reshaping finance.Support us through our Sponsors! ☕

Synopsis: This episode is proudly sponsored by Quartzy. Roivant Sciences CEO Matt Gline returns to Biotech 2050 for a deeply reflective conversation with host Rahul Chaturvedi on what it really takes to build a biotech company that lasts. From Roivant's transformational $7B Pfizer-to-Roche deal to delivering registrational Phase 3 data in dermatomyositis—one of biotech's most difficult graveyard indications—Matt shares how disciplined execution, decentralization, and learning from failure shaped Roivant's trajectory. The discussion explores Roivant's unique “Vant” model, why multiple CEOs can outperform centralized command-and-control structures, and how thoughtful clinical trial design—down to steroid tapering and site execution—can make or break outcomes in rare disease development. Beyond science and strategy, Matt reflects candidly on his own evolution as CEO, the realities of leading a public biotech through volatile markets, and why authenticity, focus, and embracing hard lessons matter more than chasing hype. This episode is a masterclass in biotech leadership, clinical development, and long-term value creation. Biography: Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy. Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

DescriptionWelcome to this episode of The Edge of Show, where we dive into the forces reshaping AI, Web3, and the future of digital trust. We're joined by Sandy Carter to break down the biggest shifts happening right now in AI, blockchain, and digital identity. We get into IBM's $11B Confluent acquisition, how AI agents are already making decisions inside major companies, and why stablecoins just surpassed Visa and Mastercard in global settlement volume.We also cover Sandy's predictions for 2026: the rise of autonomous agents, the trust layer blockchain provides, decentralized robots, and why every company will need real-time verification. Plus, Sandy gives us an inside look at what's next for Unstoppable Domains as identity moves fully on-chain.If you want a clear, no-nonsense breakdown of where the digital economy is actually heading, this episode is it.Tune in now and join the conversation!

Scott Capozza and I could have been cloned in a bad lab experiment. Both diagnosed with cancer in our early twenties. Both raised on dial-up and mixtapes. Both now boy-girl twin dads with speech-therapist wives and a lifelong grudge against insurance companies. Scott is the first and only full-time oncology physical therapist at Yale New Haven Health, which means if he catches a cold, cancer rehab in Connecticut flatlines. He's part of a small, stubborn tribe of providers who believe movement belongs in cancer care, not just after it. We talked about sperm banking in the nineties, marathon training during chemo, and what it means to be told you're “otherwise healthy” when your lungs, ears, and fertility disagree. Scott's proof that survivorship is not a finish line. It's an endurance event with no medals, just perspective.RELATED LINKSScott Capozza on LinkedIn: https://www.linkedin.com/in/scott-capozza-a68873257Yale New Haven Health: https://www.ynhh.orgExercising Through Cancer: https://www.exercisingthroughcancer.com/team/scott-capozza-pt-msptProfiles in Survivorship – Yale Medicine: https://medicine.yale.edu/news-article/profiles-in-survivorship-scott-capozzaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Shares of Ford on the move after the automaker announced a $19.5b write off of its electric vehicle business. What the company is focusing on now, instead. Plus Terns Pharmaceuticals announced positive results for its new cancer drug last week. The CEO joins to lay out next steps for the company.  Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

If you've ever checked the ingredients on a baked good, you know how ubiquitous eggs are. They bind, they lift, they emulsify, they hold moisture — they're simply the structural engineers of cookies, cakes, and muffins everywhere. But they're also volatile: prices spike, supply chains break, and for anyone with an egg allergy or who's avoiding eggs for animal welfare or environmental reasons, eggs aren't exactly a welcome ingredient to find on the ingredient deck.  Enter Hadar Ekhoiz Razmovich, CEO and co-founder of Meala FoodTech, an Israeli startup that's figured out how to make peas do what eggs and hydrocolloids do, and has consequently raised several million dollars in venture capital so far. Meala's breakthrough lies in taking simple pea protein and using advanced biotechnology to unlock its hidden abilities — creating a single-ingredient powder that they say can whip, bind, and gel just like an egg in baked goods and alternative meat. No multi-ingredient formulations, no methylcellulose, no animal inputs — just plants doing some biochemical magic.  In this episode, Hadar shares how her background in R&D led her to tackle one of food science's toughest challenges: replacing eggs and hydrocolloids without sacrificing texture, taste, or cost. We talk about how Meala's technology works, what it takes to convince industrial bakeries to swap eggs for peas, and why she believes clean-label ingredients like this are the future of food.  Hadar is not just rethinking what we eat, she and her team are rebuilding the food system from scratch, one cookie, cake, and croissant at a time.  Discussed in this episode  Meals is backed by The Kitchen Food Tech Hub, DSM's venture arm, Milk & Honey Ventures, Lasenor, and EIT.  Our past episode with Milk & Honey Ventures' Beni Nofech.  More on Meala's egg replacer, GroundBaker, is here.  You can see two pending patent applications of Meala's here and here.    Get to know Hadar Ekhoiz Razmovich  Hadar Ekhoiz Razmovich brings over 12 years of leadership experience in the global food industry, with a strong focus on driving innovation and R&D across traditional food sectors. Throughout her career, she has led complex, multidisciplinary projects from early concept development to full commercial launch, consistently bridging technological capabilities with real market needs.  In 2021, she founded Meala FoodTech with a mission to transform the food industry. Under her leadership, Meala is pioneering clean-label functional protein that deliver superior texture, bite, and mouthfeel—without compromise and without undesirable additives. Her work empowers food manufacturers to create simpler, more natural, and better-tasting products, setting a new benchmark for next-generation of food.  Hadar is widely recognized for her strategic vision, deep industry insight, and ability to translate scientific innovation into scalable commercial solutions. 

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Bruce Culleton, M.D., CEO at ProKidney, talks about moving from academic research to industry and the role a key mentor played in his career path. Bruce discusses his experiences as a first-time CEO at ProKidney, a late-stage autologous cell therapy biotech focused on pioneering new treatments for chronic kidney disease (CKD), the benefits of FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, how delaying or avoiding kidney dialysis would be a game-changer for CKD patients, and more.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Welcome to this episode of The Edge of Show, where we dive into the forces reshaping AI, Web3, and the future of digital trust. We're joined by Sandy Carter to break down the biggest shifts happening right now in AI, blockchain, and digital identity. We get into IBM's $11B Confluent acquisition, how AI agents are already making decisions inside major companies, and why stablecoins just surpassed Visa and Mastercard in global settlement volume.We also cover Sandy's predictions for 2026: the rise of autonomous agents, the trust layer blockchain provides, decentralized robots, and why every company will need real-time verification. Plus, Sandy gives us an inside look at what's next for Unstoppable Domains as identity moves fully on-chain.If you want a clear, no-nonsense breakdown of where the digital economy is actually heading, this episode is it.Tune in now and join the conversation!

Join us for an insightful episode of The Edge of Show as we dive into the world of decentralized AI finance with Ron Bodkin, co-founder and CEO of Theoriq Labs. With over 15 years of experience in applied AI, Ron shares his journey from working at tech giants like Google to pioneering a decentralized AI protocol that empowers autonomous agents to manage capital and execute strategies on-chain.In this episode, we explore:The intersection of AI and blockchain technologyThe importance of decentralization in the future of financeHow Theoriq Labs is leveraging AI agents to enhance DeFi strategiesThe challenges and opportunities in creating a decentralized ecosystemInsights into the future of capital markets and the role of AI agentsWhether you're a crypto enthusiast, a tech innovator, or just curious about the future of finance, this episode is packed with valuable insights and thought-provoking discussions.Don't forget to like, subscribe, and hit the notification bell to stay updated on our latest episodes!Support us through our Sponsors! ☕

Welcome to this episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) event in Washington, D.C. In this conversation,Josh Kriger is joined by Craig Salm, Ryan VanGrack, Kyle Hauptman, and Jon Ungerland for a candid breakdown of the rapidly evolving world of FinTech, blockchain, and digital assets. Together, they dig into regulatory clarity, the rise of DeFi, shifting consumer behaviors, and what recent policy moves mean for the future of money.Key Highlights:How regulatory uncertainty impacts builders, investors, and institutionsThe rise of DeFi and new expectations around decentralized servicesWhat recent SEC changes signal for digital assetsHow local financial institutions adapt to new money networksPredictions for the future of money and innovation in U.S. financeThis episode is for policymakers, innovators, and industry leaders who want to explore how emerging technologies are reshaping finance.Support us through our Sponsors! ☕

Welcome to this episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) event in Washington, D.C. In this conversation,Josh Kriger is joined by Craig Salm, Ryan VanGrack, Kyle Hauptman, and Jon Ungerland for a candid breakdown of the rapidly evolving world of FinTech, blockchain, and digital assets. Together, they dig into regulatory clarity, the rise of DeFi, shifting consumer behaviors, and what recent policy moves mean for the future of money.Key Highlights:How regulatory uncertainty impacts builders, investors, and institutionsThe rise of DeFi and new expectations around decentralized servicesWhat recent SEC changes signal for digital assetsHow local financial institutions adapt to new money networksPredictions for the future of money and innovation in U.S. financeThis episode is for policymakers, innovators, and industry leaders who want to explore how emerging technologies are reshaping finance.Support us through our Sponsors! ☕